A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Clinical trial NCT03451084 · COMPLETED

Trial details

NCT number: NCT03451084
Sponsor: ASLAN Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2018-01-05
Primary completion: 2019-09-11
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.